Calm Study: Secondary Endpoints of a Phase Ii Study of a Novel Oncolytic Immunotherapeutic Agent, Coxsackievirus A21, Delivered Intratumorally in Patients with Advanced Malignant Melanoma
Year: 2014
Type: article
Study design: Clinical Trial
Source: Annals of Oncology
Authors: R.H. Andtbacka, B. Curti, H. Kaufman, G.A. Daniels, J.J. Nemunaitis, L.E. Spitler, S. Hallmeyer, J. Lutzky, S. Schultz, E.D. Whitman, K. Zhou, J.I. Weisberg, D. Shafren
Institutions: Huntsman Cancer Institute, Providence Portland Medical Center, Rush University Medical Center, University of California San Diego, Moores Cancer Center, Mary Crowley Cancer Research Center, Northern California Melanoma Center, Oncology Specialists, Mount Sinai Medical Center, Atlantic Health System, Viralytics Limited (Australia)
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W1870964276